Resumen

ESCOBAR AMARALES, Yamilet et al. Heberprot-P in the treatment of diabetic foot ulcers. AMC [online]. 2014, vol.18, n.3, pp. 297-308. ISSN 1025-0255.

ABSTRACT Background: Heberprot-P® (Heber Biotec SA., Cuba) is a Cuban drug whose active pharmaceutical ingredient is the human recombinant epidermal growth factor. Objective: to enrich the existing evidences of the successful use of this drug for diabetic foot ulcers treatment in primary health care. Method: the universe was comprised of 73 patients affected by ulcers of inferior limbs. The study included 30 patients with diabetic foot ulcers, 3 and 4 stages of Wagner’s classification, treated at Julio Antonio Mella Polyclinic, Camagüey, who received several doses of 75 mg of drug by intralesional and perilesional infiltration. The studied variables were: need of surgery, epithelization time and adverse events. Results: the epithelization time of 66, 6 % of the cases was less than 50 days. Chills and tremors were observed in 50 % of the cases. The use of Heberprot-P (Heber Biotec SA., Cuba) was satisfactory in 96, 7 % of the cases. Conclusions: results showed that the use of Heberprot-P® at primary health care level is safe and does not represent any risk for the treatment of patients who reached a high percent of epithelization. Also the use of this drug at primary health care level could diminish the number of secondary care admissions and major amputations associated with diabetic foot ulcers.

Palabras clave : EPIDERMAL GROWTH FACTOR [therapeutic use]; DIABETIC FOOT [therapy]; PRIMARY HEALTH CARE; DIABETES MELLITUS; ADULT; LONGITUDINAL STUDIES.

        · resumen en Español     · texto en Español     · Español ( pdf )